Kinetic Cytokine Secretion Profile of LPS-Induced Inflammation in the Human Skin Organ Culture.
LPS
biological biomarkers of skin inflammation
cytokine
drug development
ex vivo
human skin organ culture
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
25 Mar 2020
25 Mar 2020
Historique:
received:
09
02
2020
revised:
15
03
2020
accepted:
23
03
2020
entrez:
29
3
2020
pubmed:
29
3
2020
medline:
29
3
2020
Statut:
epublish
Résumé
Several in vitro models that mimic different aspects of local skin inflammation exist. The use of ex vivo human skin organ culture (HSOC) has been reported previously. However, comprehensive evaluation of the cytokine secretory capacity of the system and its kinetics has not been performed. Objective: the aim of the current study was to investigate the levels and secretion pattern of key cytokine from human skin tissue upon lipopolysaccharide (LPS) stimulation. HSOC maintained in an air-liquid interface was used. Epidermal and tissue viability was monitored by MTT and Lactate Dehydrogenase (LDH) activity assay, respectively. Cytokine levels were examined by ELISA and multiplex array. HSOCs were treated without or with three different LPS subtypes and the impact on IL-6 and IL-8 secretion was evaluated. The compounds enhanced the secreted levels of both cytokines. However, differences were observed in their efficacy and potency. Next, a kinetic multiplex analysis was performed on LPS-stimulated explants taken from three different donors to evaluate the cytokine secretion pattern during 0-72 h post-induction. The results revealed that the pro-inflammatory cytokines IL-6, IL-8, TNFα and IL-1β were up-regulated by LPS stimuli. IL-10, an anti-inflammatory cytokine, was also induced by LPS, but exhibited a different secretion pattern, peak time and maximal stimulation values. IL-1α and IL-15 showed donor-specific changes. Lastly, dexamethasone attenuated cytokine secretion in five independent repetitions, supporting the ability of the system to be used for drug screening. The collective results demonstrate that several cytokines can be used as valid inflammatory markers, regardless of changes in the secretion levels due to donor's specific alterations.
Identifiants
pubmed: 32218380
pii: pharmaceutics12040299
doi: 10.3390/pharmaceutics12040299
pmc: PMC7238050
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministry of Science and Technology, Israel
ID : 580458776
Organisme : ICA foundation
ID : n/a
Organisme : Clinic Lenom
ID : n/a
Déclaration de conflit d'intérêts
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Références
Sci Signal. 2008 Dec 23;1(51):pe55
pubmed: 19109238
Front Cell Infect Microbiol. 2017 Sep 14;7:404
pubmed: 28959685
Exp Dermatol. 2008 Dec;17(12):1063-72
pubmed: 19043850
Skin Res Technol. 2003 Nov;9(4):321-30
pubmed: 14641882
J Biomed Sci. 2010 Jul 01;17:53
pubmed: 20594301
Cold Spring Harb Perspect Biol. 2012 Mar 01;4(3):
pubmed: 22296764
J Biol Chem. 2012 Jun 8;287(24):20208-20
pubmed: 22523073
J Allergy Clin Immunol. 2009 Feb;123(2):486-92
pubmed: 18986691
Blood. 2010 Sep 9;116(10):1715-25
pubmed: 20538798
J Cosmet Dermatol. 2020 Jun;19(6):1522-1527
pubmed: 31603269
J Epidemiol Community Health. 2002 Dec;56(12):890
pubmed: 12461097
Photochem Photobiol. 2002 Jul;76(1):57-63
pubmed: 12126308
Brief Funct Genomics. 2013 Nov;12(6):489-98
pubmed: 23943603
Nat Rev Immunol. 2014 May;14(5):289-301
pubmed: 24722477
J Med Microbiol. 2006 Sep;55(Pt 9):1175-1185
pubmed: 16914646
Arch Dermatol Res. 2001 Apr;293(4):184-90
pubmed: 11380151
Drug Discov Today. 2011 Feb;16(3-4):132-9
pubmed: 21146629
J Immunol. 2010 Mar 24;184(9):5263-5270
pubmed: 20335534
Inflamm Res. 2012 Jul;61(7):735-42
pubmed: 22453842
Exp Dermatol. 2011 Sep;20(9):749-55
pubmed: 21707755
Wound Repair Regen. 2008 Jul-Aug;16(4):559-67
pubmed: 18638275
J Immunol. 2008 May 1;180(9):5771-7
pubmed: 18424693
Vascul Pharmacol. 2015 Aug;71:31-6
pubmed: 25869514
Biomol Ther (Seoul). 2012 Jan;20(1):118-24
pubmed: 24116284
Adv Dermatol. 2008;24:71-87
pubmed: 19256306
Skin Pharmacol Physiol. 2019;32(4):173-181
pubmed: 31079103
Eur J Pharm Biopharm. 2005 Jul;60(2):167-78
pubmed: 15913972
Vaccine. 2009 Oct 9;27(43):5948-55
pubmed: 19679220
Indian J Dermatol. 2011 Jul;56(4):368-74
pubmed: 21965841
Exp Dermatol. 2012 Nov;21(11):892-4
pubmed: 23163661
J Leukoc Biol. 2004 Sep;76(3):616-22
pubmed: 15178702
Nat Med. 2015 Jul;21(7):719-29
pubmed: 26121196
Clinics (Sao Paulo). 2011;66(1):77-82
pubmed: 21437440
J Appl Biomater Funct Mater. 2016 Apr 06;14(1):e9-18
pubmed: 26689817
J Immunol. 2006 Feb 1;176(3):1908-15
pubmed: 16424222
Adv Drug Deliv Rev. 2014 Apr;69-70:81-102
pubmed: 24378581
Postepy Dermatol Alergol. 2014 May;31(2):84-91
pubmed: 25097473
J Biol Chem. 2004 Jul 30;279(31):32633-42
pubmed: 15145954
Front Microbiol. 2019 Jun 05;10:1172
pubmed: 31231322
Oncol Lett. 2010 Mar;1(2):289-292
pubmed: 22966296